SCHEMBL8816364

SCHEMBL8816364

CCCCc1ccc(CCCCCCOc2cccc3c2C(=O)NC3=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPRB P23467 1/20 0.40
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ KCNA3 P22001 1/20 0.39
▸ ELANE P08246 4/20 0.38
▸ PRKCA P17252 5/20 0.38
▸ HPGD P15428 1/20 0.38
▸ PDE5A O76074 1/20 0.37
▸ PDE4A P27815 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ PDE4C Q08493 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ NR1I2 O75469 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ ADRA2A P08913 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ OPRK1 P41145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4593117 0.90 PRKCA (0.45) KCNA3ELANEPRKCAHPGDPDE5A
SCHEMBL7648225 0.82 CYP2A6 (0.43) KCNA3ELANEHPGDPDE5APDE4A
SCHEMBL9603526 0.80 HTR1B (0.48) KCNA3ELANECHRM2
SCHEMBL7399139 0.76 DDB1 (0.46) HPGDMEN1MAPTKMT2A
SCHEMBL9596671 0.76 KCNA3 (0.42) MAOAMAOBKCNA3ELANEHPGD
Water SCHEMBL8678456 0.75 DDB1 (0.45) HPGDMEN1MAPTKMT2A
SCHEMBL10776993 0.74 CDK2 (0.43) KCNA3HPGDPDE5AMEN1KMT2A
SCHEMBL11064554 0.74 KCNA3 (0.40) MAOAMAOBKCNA3HPGD
SCHEMBL17154508 0.73 KCNA3 (0.40) KCNA3HPGDLMNACHRM2
SCHEMBL17154500 0.73 HTR7 (0.51) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1997010247-A1 CLAVULANIC ACID DERIVATIVES FOR TREATING ATHEROSCLEROSIS SMITHKLINE BEECHAM P.L.C. (GB) 1997-03-20 — — WO disclosed
Send feedback